Polypharmacy and deprescribing in primary care
- Tool
Every extra medicine adds risk. The family doctor sees the whole list and is the one who can safely stop what no longer helps.
What it is
Polypharmacy is the regular use of many medicines, most often defined as five or more, a count that says nothing about whether they are right. WHO separates appropriate polypharmacy (every medicine serves a goal agreed with the patient, the goal is met or likely, harm is minimised, and the patient can and will take it) from inappropriate polypharmacy (a medicine with no current indication, one that fails its goal, one that causes or risks adverse effects, or one the patient cannot or will not take). Deprescribing is the planned process of tapering, reducing or stopping medicines to manage polypharmacy and improve outcomes, done with the patient and monitored.
What it measures and how to read it
- The count (often five or more regular medicines) flags risk; appropriateness is judged medicine by medicine.
- WHO patient-centred review in 7 steps: aims (what matters), need (essential and unnecessary medicines), effectiveness, safety, cost, and whether the patient is willing and able to take them.
- Essential medicines (those replacing a missing function or preventing rapid decline, such as thyroid hormone or Parkinson's treatment) are not stopped without specialist advice.
- Explicit criteria screen the list: STOPP lists potentially inappropriate medicines and START potential omissions (version 2: 80 and 34 criteria, by body system); the Beers criteria list medicines to avoid in older adults.
- The whole list means the whole list: over-the-counter, herbal and traditional products count.
Worked example
- Doña Rosa (made up), 78, brings every box: 11 products from three prescribers and the pharmacy, including a painkiller and antihistamine nobody prescribed.
- What matters to her: to keep living alone and stop falling. Her diabetes and blood-pressure goals are reframed around that.
- Need: a stomach-acid reducer was started in hospital two years ago with no ongoing reason; a sleeping pill (benzodiazepine) has been «temporary» for six years.
- Effectiveness: her glucose runs low at night on a sulfonylurea; at her age, tight control is now giving more harm (hypoglycaemia, falls) than benefit.
- Safety: the anti-inflammatory with her ACE inhibitor and diuretic threatens her kidneys; sedative plus anticholinergic plus hypoglycaemia explain the falls.
- STOPP flags the long-term benzodiazepine, the anti-inflammatory and the sedating antihistamine; START asks what is missing, such as vaccines.
- One change at a time, agreed with her: taper the benzodiazepine with sleep advice, replace the anti-inflammatory, then review the sulfonylurea and acid reducer.
- Teach-back and one written list for her, her daughter and the pharmacy; tell the other prescribers what changed and why.
- Follow-up visit: sleep, pain, glucose, blood pressure, kidney function, withdrawal symptoms and falls; any new medicine is treated as a trial.
Tools for reviewing a medicine list
| Tool | Type | What it does | Limit |
|---|---|---|---|
| STOPP/START (version 2) | Explicit, by body system | STOPP flags potentially inappropriate medicines; START flags useful ones that are missing | Screens the list; does not know the patient's goals |
| Beers criteria | Explicit | Lists medicines to avoid in older adults, by drug class and by disease | Mainly «what to avoid»; says little about omissions |
| WHO 7-step review | Implicit, patient-centred | Walks from the patient's aims through need, effectiveness, safety, cost and adherence | Takes time; depends on the reviewer's judgement |
| Medication Appropriateness Index | Implicit | Ten questions about each medicine | Patient-centred but slow in a busy clinic |
When to use it
- At every new prescription, after every hospital discharge or change of care setting, and at the older adult's periodic assessment (Res. 3280 asks for a review of all prescribed, self-prescribed and herbal products at each consultation).
- When a new symptom appears in someone taking many medicines: suspect a drug before a new disease (prescribing cascade).
- When the person's goals change: frailty, dementia, the last months of life.
Common pitfalls
- Reviewing only the prescription: over-the-counter, herbal and traditional products are missed.
- Stopping several medicines at once: if something goes wrong you cannot tell which change caused it.
- Stopping an essential medicine (thyroid hormone, Parkinson's treatment) without specialist advice.
- Not telling the other prescribers, who then restart the medicine.
Common traps
- Five or more medicines is always bad: the count flags risk, but many people with several diseases need many medicines (appropriate polypharmacy)
- Deprescribing is simply stopping drugs: it is a planned, monitored process agreed with the patient, often by tapering, and a review may also add a missing medicine
- A new symptom in an older adult is a new disease to treat: it may be an adverse effect, and treating it with another drug starts a prescribing cascade
- STOPP/START replaces clinical judgement: explicit criteria screen the list, but the decision rests on the patient's goals, function and prognosis
Test yourself
Think of the answer, then tap the question to see it.
Why is «five or more medicines» not enough to call a treatment inappropriate?
The count only flags risk. WHO judges each medicine: does it serve an agreed goal, is the goal met, is harm minimised, and can the patient take it as intended?
An 80-year-old starts falling after a sleeping pill is added to her antihistamine and blood-pressure medicines. What comes first?
A medication review asking whether the drugs explain the falls (sedation, anticholinergic effects, low blood pressure) before adding any treatment for the new symptom.
What does START add that STOPP does not?
START lists potential prescribing omissions, useful treatments that may be missing, so a review can also add a medicine.
Why change one medicine at a time when deprescribing?
So that any withdrawal effect, return of symptoms or improvement can be linked to that change and acted on.
Elsewhere in DurgiPedia
- Medication reconciliation
- Comprehensive geriatric assessment: function, cognition, falls
- Adherence: what it is and why it fails
Connections
Educational content on the family-medicine and primary-care approach. Not a clinical or legal guide: current Colombian care pathways and rules are in the official sources.
Sources: Medication safety in polypharmacy: technical report (WHO/UHC/SDS/2019.11) (World Health Organization, 2019); STOPP/START criteria for potentially inappropriate prescribing in older people: version 2 (O'Mahony D et al., Age and Ageing) (Age and Ageing (PubMed Central, open access), 2015); Polypharmacy: evaluating risks and deprescribing (Halli-Tierney AD et al., Am Fam Physician 100(1):32-38) (American Academy of Family Physicians, 2019); Resolución 3280 de 2018 (compilación con las modificaciones de la Resolución 276 de 2019) (Superintendencia Nacional de Salud, Colombia (Compilación Jurídica, normograma), 2018).
Spotted a mistake?We are always improving for the community. Tell us what is wrong and our team will review it.Report a mistake
Representative model, for educational purposes only.
